Sanofi makes $9.3-billion bid for San Francisco drug company Medivation
French pharmaceutical giant Sanofi said on Thursday it had made a bid to acquire San Francisco-based drugmaker Medivation.
- Share via
Reporting from Paris — Drug maker Sanofi says it has made a $9.3-billion bid for San Francisco pharmaceutical firm Medivation, part of the firm’s effort to expand its portfolio of cancer treatments.
Medivation Inc. has so far resisted overtures from Paris-based Sanofi, which is seeking to compete with the likes of America’s Bristol-Myers Squibb, Switzerland’s Roche and Britain’s AstraZeneca, all three of which have poured money into cancer drug research.
Sanofi Chief Executive Olivier Brandicourt says in an open letter to Medivation Chief Executive David T. Hung that the all-cash offer is for $52.50 per share. He says that the deal would give Medivation’s cancer treatments — notably Xtrandi — the benefit of Sanofi’s “global capabilities [and] significant resources.”
There was no immediate reaction from Medivation.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
